Tempus AI (NASDAQ:TEM) Shares Climb 6.1% – What’s Next?

Tempus AI, Inc. (NASDAQ:TEM)’s stock price traded up 6.1% on Thursday. The stock traded as high as $81.25 and last traded at $81.2690. 8,574,459 shares changed hands during mid-day trading, an increase of 40% from the average daily volume of 6,142,033 shares. The stock had previously closed at $76.59.

Key Headlines Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Leica Biosystems added Tempus pathology products to its Aperio AI Store, making Tempus’ AI-powered pathology capabilities available through Leica’s digital pathology ecosystem. The collaboration could improve distribution and adoption of Tempus tools among oncology researchers and healthcare providers, reinforcing the company’s precision-medicine growth story. Leica Biosystems brings Tempus pathology products to Aperio AI Store
• Positive Sentiment: Investor enthusiasm remained strong around TEM’s artificial-intelligence and healthcare exposure, with the stock rising even as reports highlighted the CEO’s share sale. Tempus has also been featured in investment articles focused on AI-powered medical companies, supporting its growth narrative. Tempus AI stock rises despite CEO share sale
• Neutral Sentiment: Recent analyst commentary is mixed. Several firms maintain buy or overweight ratings and price targets near or above recent trading levels, but the reported consensus rating remains “Hold,” with an average target below the stock’s latest quoted level. Tempus also remains unprofitable, although its latest reported revenue increased year over year and earnings exceeded expectations.
• Negative Sentiment: CEO Eric Lefkofsky sold 250,000 shares for approximately $19.4 million, reducing his direct ownership by 71.43%. The sale was conducted under a pre-arranged Rule 10b5-1 plan, which makes it less indicative of a discretionary bearish view, but the size of the transaction may still weigh on sentiment. Tempus AI CEO sells 250,000 shares
• Negative Sentiment: The chief accounting officer also reportedly sold approximately $529,650 of TEM stock, adding to concerns about insider selling during a period of elevated valuation. Tempus AI chief accounting officer sells stock

Analyst Ratings Changes

Several research firms have recently commented on TEM. Needham & Company LLC reaffirmed a “buy” rating and set a $75.00 price target on shares of Tempus AI in a research report on Friday, July 31st. Wall Street Zen upgraded shares of Tempus AI from a “sell” rating to a “hold” rating in a report on Saturday, July 25th. The Goldman Sachs Group started coverage on Tempus AI in a report on Monday, September 21st. They issued a “neutral” rating and a $75.00 price objective on the stock. Raymond James Financial set a $80.00 target price on Tempus AI in a research note on Wednesday, September 2nd. Finally, Guggenheim raised their target price on Tempus AI from $60.00 to $65.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Eleven equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Tempus AI currently has a consensus rating of “Hold” and an average target price of $69.63.

Tempus AI Stock Up 3.4%

The business’s 50 day moving average is $59.62 and its 200-day moving average is $53.86. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16. The company has a market cap of $15.34 billion, a PE ratio of -59.03 and a beta of 3.72.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. The company had revenue of $382.49 million for the quarter, compared to the consensus estimate of $379.69 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The company’s quarterly revenue was up 21.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.22) EPS. As a group, analysts predict that Tempus AI, Inc. will post -1.38 EPS for the current year.

Insider Activity at Tempus AI

In other Tempus AI news, CFO James Rogers sold 26,313 shares of the stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $60.00, for a total value of $1,578,780.00. Following the transaction, the chief financial officer directly owned 106,024 shares in the company, valued at $6,361,440. This represents a 19.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Ryan Fukushima sold 41,095 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $49.61, for a total transaction of $2,038,722.95. Following the sale, the chief executive officer directly owned 562,463 shares in the company, valued at approximately $27,903,789.43. The trade was a 6.81% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 1,490,499 shares of company stock valued at $92,463,782 over the last three months. 24.26% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. QRG Capital Management Inc. purchased a new position in shares of Tempus AI during the second quarter worth approximately $240,000. WINTON GROUP Ltd purchased a new position in Tempus AI during the 2nd quarter worth $342,000. Engineers Gate Manager LP acquired a new stake in shares of Tempus AI in the 2nd quarter worth $637,000. Integrated Wealth Concepts LLC purchased a new stake in shares of Tempus AI in the second quarter valued at about $145,000. Finally, Baird Financial Group Inc. boosted its holdings in shares of Tempus AI by 3.4% in the second quarter. Baird Financial Group Inc. now owns 30,434 shares of the company’s stock valued at $1,763,000 after acquiring an additional 994 shares in the last quarter. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company focused on applying artificial intelligence and data analytics to precision medicine. The company combines molecular testing, clinical data and machine learning to help physicians make more informed treatment decisions and support the development of new therapies.

Tempus provides genomic and diagnostic testing services, including testing intended to identify clinically relevant mutations and other biomarkers. Its technology platform also organizes and analyzes clinical and molecular data, while its AI-enabled tools are designed to assist healthcare professionals with patient care, research and workflow management.

The company serves healthcare providers, patients, pharmaceutical companies and biotechnology researchers, primarily in the United States.